What are MNC pharma China strategy trends?

Multinational pharmaceutical companies are changing the way they approach China. For many years, China strategy for MNC pharma was mainly about bringing global products into the Chinese market, building commercial teams, navigating regulatory approval, and expanding hospital access. That model still matters, but it is no longer enough.

Today, China is not only a sales market. It is becoming a source of innovation, a business development hub, a clinical collaboration base, and a strategic partner ecosystem for global pharma.

One clear trend is the rise of China-focused BD. Multinational companies are increasingly looking to Chinese biotech firms for innovative assets, technology platforms, and clinical-stage candidates. The logic is simple: China’s biotech ecosystem has matured quickly, and many local companies now have differentiated capabilities in oncology, autoimmune diseases, antibody drugs, ADCs, molecular glues, cell therapy, small molecules, and AI-enabled drug discovery.

Merck’s recent China activity is a strong example. According to VCBeat’s documents, Merck Research China announced cooperation with four Chinese companies in one day, including clinical development collaborations in autoimmune diseases and oncology. The signal is clear: MNCs are moving from “bringing products into China” toward “building innovation together with China.”

This marks a structural shift. In the first phase, MNC-China biotech cooperation was often based on licensing: one company paid upfront and milestone fees to obtain rights to an asset. In the second phase, more deals moved toward co-development. Now, the market is entering a deeper stage, where MNCs work with local companies on clinical development, platform validation, and strategic pipeline building.

Another trend is local empowerment. In the Merck case, the signing entity was Merck Research China, not only the global headquarters. This suggests that China-based MNC teams are gaining more influence in business development and R&D decision-making. As China becomes a more important innovation source, local teams need greater autonomy to identify opportunities, evaluate assets, and move quickly.

A third trend is lightweight commercialization through local partners. Teva’s AJOVY partnership in China illustrates this model. Instead of building a full commercial organization for AJOVY in mainland China, Teva granted local commercialization rights to a Chinese partner. For MNCs, this kind of structure can reduce cost and operational risk while still giving access to the Chinese market. For local partners, it provides a chance to prove commercial capability with a globally validated product.

This model is especially relevant in therapeutic areas that require deep local execution. China market access involves pricing, reimbursement, hospital access, physician education, patient management, and compliance. A global brand alone is not enough. MNCs increasingly need local partners that understand clinical networks, payer dynamics, and patient behavior.

A fourth trend is the growing importance of China as a strategic R&D node. MNCs are no longer only searching for late-stage products. They are paying attention to early-stage mechanisms, platform technologies, and clinical collaboration opportunities. Areas such as molecular glue, ADC, antibody drugs, autoimmune disease therapies, and next-generation oncology assets are becoming important fields of collaboration.

A fifth trend is stronger focus on ecosystem positioning. VCBeat’s MNC China Lens column is designed around company-level and event-level tracking, including BD, investment, collaboration, market activity, and product approvals. This reflects a broader market reality: MNC strategy in China must now be understood through multiple dimensions, not only sales performance.

For global pharma companies, China strategy is becoming more complex. They must balance product introduction, local partnerships, external innovation sourcing, regulatory adaptation, pricing pressure, commercialization efficiency, and long-term ecosystem credibility. The companies that succeed will be those that treat China as both a market and an innovation partner.

For Chinese biotech and pharma companies, this creates new opportunities. MNCs are increasingly willing to collaborate with local innovators, not only to access China, but also to strengthen global pipelines. A partnership with a multinational company can provide capital, clinical development support, global regulatory experience, and international validation.

The future of MNC pharma China strategy will likely be defined by three words: partnership, localization, and innovation. Partnership means deeper cooperation with Chinese companies. Localization means using China-specific commercial and regulatory strategies. Innovation means recognizing China as a source of globally relevant science, not merely a destination for imported products.

MNC pharma companies are no longer just entering China. They are learning to build with China.